Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Teriparatide and osseous regeneration in the oral cavity.

Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK.

N Engl J Med. 2010 Dec 16;363(25):2396-405. doi: 10.1056/NEJMoa1005361. Epub 2010 Oct 16.

2.

Teriparatide for bone loss in the jaw.

Grey A.

N Engl J Med. 2010 Dec 16;363(25):2458-9. doi: 10.1056/NEJMe1010459. Epub 2010 Oct 16. No abstract available.

PMID:
20950165
3.

Teriparatide and osseous regeneration in the jaw.

Finkelman RD, Reddy MS.

N Engl J Med. 2011 Mar 17;364(11):1080; author reply 1080-1. doi: 10.1056/NEJMc1100728#SA1. No abstract available.

PMID:
21410380
4.

Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.

Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, Krohn KD, Warner MR, Ahmad QI, Mitlak B.

Clin Orthop Relat Res. 2016 May;474(5):1234-44. doi: 10.1007/s11999-015-4669-z. Epub 2016 Mar 1.

5.

The impact of vitamin D status on periodontal surgery outcomes.

Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK.

J Dent Res. 2011 Aug;90(8):1007-12. doi: 10.1177/0022034511407771. Epub 2011 May 9.

6.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

7.

Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.

Cheung A, Seeman E.

N Engl J Med. 2010 Dec 16;363(25):2473-4. doi: 10.1056/NEJMc1002684. Epub 2010 Oct 16. No abstract available.

8.

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

Keel C, Kraenzlin ME, Kraenzlin CA, Müller B, Meier C.

J Bone Miner Metab. 2010;28(1):68-76. doi: 10.1007/s00774-009-0101-7. Epub 2009 Jun 17.

PMID:
19633810
9.

More on the resolution of bisphosphonate-associated osteonecrosis of the jaw.

Tsai KY, Huang CS, Huang GM, Yu CT.

J Rheumatol. 2010 Mar;37(3):675; author reply 676. doi: 10.3899/jrheum.091022. No abstract available.

PMID:
20197569
10.

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.

Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2.

11.

Teriparatide therapy for osteonecrosis of the jaw.

Chtioui H, Lamine F, Daghfous R.

N Engl J Med. 2011 Mar 17;364(11):1081-2; author reply 1082. doi: 10.1056/NEJMc1100730#SA1. No abstract available.

PMID:
21410382
12.

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.

PMID:
25393645
13.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
14.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

15.

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group.

Osteoporos Int. 2011 Jun;22(6):1935-46. doi: 10.1007/s00198-010-1379-y. Epub 2010 Oct 12.

16.

Systemic Teriparatide Administration Promotes Osseous Regeneration of an Intrabony Defect: A Case Report.

Bashutski JD, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK, Eber RM.

Clin Adv Periodontics. 2012 May;2(2):66-71.

17.

Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G.

Med Sci Monit. 2011 Aug;17(8):CR442-448.

18.

Anabolic therapy for osteoporosis.

Bilezikian JP.

Int J Fertil Womens Med. 2005 Mar-Apr;50(2):53-60. Review.

PMID:
16334411
19.

Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.

Aspenberg P, Malouf J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Caeiro JR, Marin F.

J Bone Joint Surg Am. 2016 Nov 16;98(22):1868-1878.

20.

Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH.

Osteoporos Int. 2014 May;25(5):1625-32. doi: 10.1007/s00198-014-2622-8. Epub 2014 Feb 20.

PMID:
24554340

Supplemental Content

Support Center